Recetario nutritivo, económico y saludable / Cookbook: Nutritional, economic and healthy

En el presen recetario se incluyen preparaciones a base de pescado, pota, menestras, pollo, sangre de pollo, vísceras, carnes, leche, huevo y queso que brindan un buen aporte de energía, proteínas y hierro al más bajo costo. Estos nutrientes permiten prevenir la anemia y la desnutrición(AU)

Recetario nutritivo, económico y saludable / Cookbook: Nutritional, economic and healthy

En el recetario se incluyen preparaciones a base de pescado, pota, menestras, pollo, sangre de pollo, vísceras, carnes, leche, huevo y queso que brindan un buen aporte de energía, proteínas y hierro al más bajo costo. Estos nutrientes permiten prevenir la anemia y la desnutrición

Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole.

INTRODUCTION: Treatment with neuroleptics may be associated with secondary sexual dysfunction. Studies of sexual dysfunction induced by antipsychotic are important to establish the effectiveness of these agents in patients taking chronic treatments. The main objective of this study was to evaluate prospectively whether a 3 month course ofaripiprazole produces changes in the sexual function of patients with schizophrenia. METHODS: The efficacy analysis was performed in the intention-to-treat population (41 patients) and the per protocol population (36 patients). The safety analysis was based on the total sample (42 patients). RESULTS: The incidence of sexual dysfunction after 3 months of treatment with aripiprazole was zero both in patients who switched therapy due to lack of efficacy and in those taking aripiprazole as a first antipsychotic. Aripiprazole led to an improvement in the symptoms of psychosis (score on the BPRS) and lower scores on the SALSEX questionnaire.The most remarkable improvement was in delayed eyaculation/orgasm. CONCLUSION: During the 3 months of treatment, we observed an overall improvement in sexual performance, with a quicker recovery in men than in women, although recovery was similar in both at the end of treatment.

Estudio sobre la función sexual de pacientes que inician tratamiento con aripiprazol. Estudio naturalístico, abierto, prospectivo y multicéntrico / Observational, Open-Label, Prospective Multicenter Study of Sexual Function in Patients Starting Treatment with Aripiprazole

Introducción. El tratamiento con neurolépticos puede asociarse a disfunción sexual secundaria. Los estudios sobre la disfunción sexual secundaria a antipsicóticos son importantes para poder establecer la eficiencia de estos fármacos en los tratamientos crónicos. El objetivo principal de este estudio ha sido valorar de forma prospectiva si el aripiprazol produce modificaciones en la función sexual de los pacientes con esquizofrenia 3 meses después de su instauración. Métodos. El análisis de eficacia se efectuó en dos poblaciones, la población para intención de tratamiento (41pacientes) y la población por protocolo (36 pacientes). El análisis de seguridad se ha realizado en la muestra total (42 pacientes). Resultados. Incidencia nula de disfunción sexual a los 3 meses de tratamiento con aripiprazol, tanto en los pacientes que recibían aripiprazol como primer antipsicótico como en los que habían cambiado a aripiprazol debido a una falta de eficacia de otro antipsicótico. Además de producir una mejoría de los síntomas de psicosis (escala BPRS), el aripiprazol disminuyó la puntuación en la escala SALSEX, siendo el retraso en la eyaculación u orgasmo el que presentó una mejoría media más marcada. Conclusiones. Mejoría global del funcionamiento sexual durante los 3 meses de tratamiento con aripiprazol, que muestra una recuperación más rápida en los hombres que en las mujeres, aunque ambos consiguen una recuperación similar (AU)

Introduction. Treatment with neuroleptics maybe associated with secondary sexual dysfunction. Studies of sexual dysfunction induced by antipsychotic are important to establish the effectiveness of these agents in patients taking chronic treatments. The main objective of this study was to evaluate prospectively whether a 3 month course of aripiprazole produces changes in the sexual function of patients with schizophrenia. Methods. The efficacy analysis was performed in the intention-to-treat population (41 patients) and the perprotocol population (36 patients). The safety analysis was based on the total sample (42 patients). Results. The incidence of sexual dysfunction after 3months of treatment with aripiprazole was zero both in patients who switched therapy due to lack of efficacy and in those taking aripiprazole as a first antipsychotic. Aripiprazole led to an improvement in the symptoms of psychosis (score on the BPRS) and lower scores on the-SALSEX questionnaire. The most remarkable improvement was in delayed eyaculation /orgasm. Conclusion. During the 3 months of treatment, we observed an overall improvement in sexual performance, with a quicker recovery in men than in women, although recovery was similar in both at the end of treatment (AU)

Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area.

OBJECTIVE: Prevalence of cardiovascular disease is high in schizophrenia. Our aim is to estimate the prevalence of cardiovascular risk factors (CVRF) among schizophrenia patients. METHOD: National cross-sectional study in patients diagnosed with schizophrenia under treatment with second generation antipsychotics and admitted to short-stay hospitalisation units. RESULTS: A sample of 733 consecutively admitted patients was enrolled; the most prevalent CVRFs were smoking 71% (95% CI: 67-74%) and hypercholesterolemia 66% (61-70%) followed by hypertriglyceridemia 26% (26-32%), hypertension 18% (15-21%) and diabetes 5% (4-7%). Metabolic syndrome showed 19% (95% CI: 16-23%) prevalence or, according to updated definitions (Clin Cornerstone 7 [2005] 36-45), 24% (95% CI: 20-28%). The rate of patients within the high-risk range of a 10-year fatal cardiovascular event was 6.5%. CVRFs under routine management were diabetes (60%), hypertension (28%) and, to a lesser extent, dyslipemia (14%). Treatment for CVRFs was associated to gender, men for hypertension OR = 25.34, p < 0.03 and women for diabetes OR = 0.02, p < 0.03. CONCLUSION: We found that CVRFs in schizophrenia were prevalent and under-diagnosed, and thus with insufficient therapeutic management.

Diagnóstico y manejo de la esquizofrenia en España: el proyecto ACEE / Diagnostic process and management of schizophrenia in Spain: the ACEE project

Introducción. A pesar de tratarse de una enfermedad con una gran repercusión sanitaria, social y familiar, en España se dispone de escasa información epidemiológica sobre los pacientes con esquizofrenia, su diagnóstico y tratamiento. El estudio ACEE (Abordaje Clínico de la Esquizofrenia en España) se ha diseñado con el objetivo principal de conocer en la práctica clínica habitual el manejo de la esquizofrenia en España.Método. El ACEE es un estudio observacional, descriptivo, transversal, multicéntrico, con datos recogidos en el curso de la práctica clínica habitual mediante un cuestionario diseñado específicamente.Resultados. Se han analizado un total de 1.937 pacientes (83% del sector público y 17% del privado). La mayoría presenta una esquizofrenia paranoide en fase de estabilización y no trabaja debido a su enfermedad. El 96% está sometido a tratamiento con antipsicóticos y un 55 % recibe además algún tipo de terapia no farmacológica. Se presentan con mayor frecuencia síntomas negativos que positivos (88 frente a 63%). Existen diferencias significativas entre el tipo de pacientes y el procedimiento de diagnóstico entre el sector público y el privado.Conclusiones. El ACEE muestra que el perfil del paciente atendido por esquizofrenia en las consultas psiquiátricas españolas es mayoritariamente varón, soltero, viviendo sin trabajo en un entorno familiar, tratado básicamente con fármacos antipsicóticos combinados con otras medicaciones y al que se practica un reducido número de exploraciones complementarias

Introduction. Although schizophrenia has a great impact on the health care, social and family levels, there is little epidemiological information on patients with schizophrenia, its diagnosis and treatment in Spain. The ACEE (Abordaje Clínico de la Esquizofrenia en España; Clinical Approach to Schizophrenia in Spain) study was designed with the primary objective of defining the management of schizophrenia in Spain from the perspective of current clinical practice. Method. ACEE is a descriptive cross-sectional multicenter observational study with data collected in the setting of current clinical practice by means of a specifically designed questionnaire. Results. A total of 1,937 patients have been studied (83% pertaining to the public sector and 17% to private one). Most subjects had paranoid schizophrenia in the stabilization phase, and did not work because of their illness. Most (96%) were receiving antipsychotic treatment and 55% also received some non-drug treatment. Negative symptoms were more frequent than positive symptoms (88% versus 63%). Significant differences were observed for type of patients and diagnostic procedures involved between the public and private health care sectors. Conclusions. The ACEE study shows that schizophrenic patients attending Spanish psychiatric centers are mainly single, non-working males who are living in their family setting. Treatment basically consists of antipsychotics combined with other drugs, and few complementary examinations are performed

[Diagnostic process and management of schizophrenia in Spain: the ACEE project]. / Diagnóstico y manejo de la esquizofrenia en España: el proyecto ACEE.

INTRODUCTION: Although schizophrenia has a great impact on the health care, social and family levels, there is little epidemiological information on patients with schizophrenia, its diagnosis and treatment in Spain. The ACEE (Abordaje Clínico de la Esquizofrenia en España; Clinical Approach to Schizophrenia in Spain) study was designed with the primary objective of defining the management of schizophrenia in Spain from the perspective of current clinical practice. METHOD: ACEE is a descriptive cross-sectional multicenter observational study with data collected in the setting of current clinical practice by means of a specifically designed questionnaire. RESULTS: A total of 1,937 patients have been studied (83% pertaining to the public sector and 17% to private one). Most subjects had paranoid schizophrenia in the stabilization phase, and did not work because of their illness. Most (96%) were receiving antipsychotic treatment and 55% also received some non-drug treatment. Negative symptoms were more frequent than positive symptoms (88% versus 63%). Significant differences were observed for type of patients and diagnostic procedures involved between the public and private health care sectors. CONCLUSIONS: The ACEE study shows that schizophrenic patients attending Spanish psychiatric centers are mainly single, non-working males who are living in their family setting. Treatment basically consists of antipsychotics combined with other drugs, and few complementary examinations are performed.

Estudio de la utilización de medicamentos en la artrosis / Study of medication utilization in osteoarthritis

Objetivo: Describir el perfil de uso de medicamentos en pacientes con artrosis periférica y evaluar la adecuación terapéutica de los tratamientos analgésicos y antiinflamatorios en España. Diseño: Estudio observacional, descriptivo, transversal y multicéntrico de ámbito estatal. Pacientes: Se estudió a 3.002 pacientes diagnosticados de artrosis periférica y tratados con analgésicos o antiinflamatorios en los últimos 3 meses. Ámbito: Consultas de atención primaria. Resultados: En el momento de realizar el estudio, el 58,2 per cent de los pacientes tomaba paracetamol, el 44,8 per cent, antiinflamatorios no esteroideos (AINE) clásicos, el 11,8 per cent, inhibidores de la ciclooxigenasa 2 (COX-2) y el 6,6 per cent, otros fármacos. El tratamiento con AINE se prescribía a pacientes más jóvenes y varones (p = 0,001), mientras que los pacientes tratados con paracetamol tenían más enfermedades gástricas de base y diabetes que los que tomaban AINE (p = 0,006 y 0,035, respectivamente); pese a ello, se registró un mayor porcentaje de acontecimientos adversos gastrointestinales en los pacientes tratados con AINE (8,5 per cent) respecto a los tratados con paracetamol (5,8 per cent) (p = 0,05). La automedicación en pacientes tratados con paracetamol es menor que en aquellos a los que se les ha prescrito AINE (54,3 frente a 63,6 per cent; p < 0,001). Un 51 per cent de los pacientes tomaba dosis de paracetamol inferiores a 3 g/día, mientras que el 48,6 per cent recibía 3-4 g/día. Conclusiones: El paracetamol es el fármaco más utilizado para el tratamiento de la artrosis periférica en España. Se usa más en personas ancianas y con enfermedades concomitantes, presenta menos acontecimientos adversos gastrointestinales y su prescripción disminuye la automedicación. Las dosis medias utilizadas son inferiores a las indicadas en las recomendaciones de ACR y EULAR (AU)

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.

A 24-week, double-blind, randomized trial was performed to compare the efficacy and tolerability of venlafaxine and paroxetine in patients with major depression or dysthymia. Outpatients aged 18-70 years with a baseline score of 17 on the 21-item Hamilton Depression Rating Scale (HAM-D) were eligible. Patients were randomly assigned to venlafaxine, 37.5 mg, in the morning and evening or paroxetine, 20 mg, in the morning and placebo in the evening, which could be increased to venlafaxine, 75 mg twice daily, or paroxetine, 20 mg twice daily, after 4 weeks. Efficacy was assessed with the 21-item HAM-D, the Montgomery-Asberg Rating Scale, the Hamilton Anxiety Rating Scale, and the Clinical Global Impressions Scale. Forty-one patients were randomized to venlafaxine and 43 to paroxetine. At week 6, a response was observed in 55% of patients on venlafaxine and 29% on paroxetine (P = 0.03). At week 12, significantly (P = 0.011) more patients in the venlafaxine group had a HAM-D remission score of 8 or less (59% versus 31%). Discontinuation for any reason occurred in 16 (39%) patients on venlafaxine and 11 (26%) on paroxetine. The most common adverse events were nausea (28%), headache (18%) and dry mouth (15%) with venlafaxine and headache (40%) and constipation (16%) with paroxetine. Venlafaxine was effective and well tolerated for the treatment of patients with mild to moderate depression or dysthymia. A consistently higher proportion of patients had a response or remission on venlafaxine than on paroxetine.